A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The scope of this Phase I/II study is to determine whether GLB-COV2-043 is a promising
booster vaccine candidate component for adult participants who have received the 2-dose
priming course of the mRNA BNT162b2 vaccine against COVID-19, or the 2-dose priming course
and a third BNT162b2 injection (i.e., as a "booster"), and, if so, to select the booster dose
for further evaluation and potential development.